Sai Life Sciences Ltd Stock Price Today (NSE: SAILIFE)
Fundamental Score
Sai Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sai Life Sciences Ltd share price today is ₹972.00, down 1.32% on NSE/BSE as of 30 March 2026. Sai Life Sciences Ltd (SAILIFE) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.38K (Cr). The 52-week high for SAILIFE share price is ₹1084.00 and the 52-week low is ₹636.10. At a P/E ratio of 64.17x, SAILIFE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.05% and a debt-to-equity ratio of 0.18.
Sai Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sai Life Sciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sai Life Sciences Share Price: A Financial Stability Analysis
The pharmaceutical industry, often considered recession-resistant due to the constant demand for healthcare, is experiencing increased scrutiny regarding drug pricing and supply chain vulnerabilities. This analysis examines the financial stability of Sai Life Sciences Ltd, focusing on its key metrics. Currently, the Sai Life Sciences share price stands at ₹849.799988. We will delve into its Price-to-Earnings (PE) ratio, Return on Capital Employed (ROCE), and performance relative to its peers.
The company's PE ratio of 64.17 suggests a relatively high valuation, indicating that investors are anticipating significant future earnings growth. It’s important to consider this within the broader context of the pharmaceutical sector and compared to companies like Mankind Pharma Ltd. While both companies operate in the pharmaceutical space, perceived management quality can significantly impact investor sentiment and, consequently, valuation.
Mankind Pharma Ltd’s higher (or lower) perceived management effectiveness could contribute to differences in their respective PE ratios. Further investigation into management track record and strategic decisions is warranted.Sai Life Sciences Ltd's ROCE of 14.05% reflects the company's efficiency in generating profits from its capital employed. This ROCE contributes to the company's economic moat – the ability to maintain competitive advantages over its peers. A consistently high ROCE suggests Sai Life Sciences Ltd can reinvest profits effectively, driving further growth and reinforcing its market position. Comparing this ROCE to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd can offer valuable insights into relative operational efficiency. However, the sustainability of this ROCE should be carefully assessed, considering factors like regulatory changes and evolving market dynamics.
This analysis forms part of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra. This audit provides a more in-depth understanding of Sai Life Sciences Ltd's financial health, incorporating factors beyond those discussed here. This assessment is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sai Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAILIFE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (19.31%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (101.98%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.88%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (18.49% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (17.57% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.88x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Institutional Confidence (FII+DII: 52.44%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 64.17x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-224.76 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sai Life Sciences Ltd Financial Statements
Comprehensive financial data for Sai Life Sciences Ltd including income statement, balance sheet and cash flow
About SAILIFE (Sai Life Sciences Ltd)
Sai Life Sciences Ltd is a globally recognized Contract Research, Development, and Manufacturing Organization deeply rooted in pharmaceutical innovation. From its strategic base in... Hyderabad, India, Sai Life Sciences propels the boundaries of drug discovery and development through a comprehensive suite of services. Their expertise spans the entire pharmaceutical lifecycle, providing customized solutions from initial target identification and lead optimization to advanced drug substance and drug product manufacturing. With a commitment to scientific excellence and agility, Sai Life Sciences partners with pharmaceutical and biotechnology companies of all sizes, accelerating their journeys toward bringing life-saving medications to market. SAILIFE distinguishes itself by integrating cutting-edge technologies and a highly skilled scientific workforce. Their capabilities encompass a wide spectrum of disciplines, including medicinal chemistry, process development, analytical research, and formulation development. This integrated approach allows for seamless transitions between different phases of drug development, ensuring efficiency and minimizing potential delays. Beyond its scientific prowess, Sai Life Sciences places a strong emphasis on regulatory compliance and quality assurance. This dedication ensures that every project adheres to the highest industry standards, providing clients with confidence in the integrity and reliability of their results. Sai Life Sciences operates on a foundation of collaboration and client-centricity. They forge strong partnerships with their clients, working as an extension of their own teams to achieve shared goals. Their focus is on delivering tailored solutions that meet the specific needs of each project, while constantly adapting to evolving market demands. By investing in state-of-the-art infrastructure and attracting top talent, Sai Life Sciences continues to solidify its position as a trusted partner in the global pharmaceutical industry, driving innovation and making a tangible difference in healthcare outcomes worldwide.
Company Details
Key Leadership
Latest News
SAILIFE Share Price: Frequently Asked Questions
What is the current share price of Sai Life Sciences Ltd (SAILIFE)?
As of 30 Mar 2026, 12:04 pm IST, Sai Life Sciences Ltd share price is ₹972.00. The SAILIFE stock has a market capitalisation of ₹18.38K (Cr) on NSE/BSE.
Is SAILIFE share price Overvalued or Undervalued?
SAILIFE share price is currently trading at a P/E ratio of 64.17x, compared to the industry average of 31.77x. Based on this relative valuation, the Sai Life Sciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SAILIFE share price?
The 52-week high of SAILIFE share price is ₹1084.00 and the 52-week low is ₹636.10. These values are updated daily from NSE/BSE price data.
What factors affect the Sai Life Sciences Ltd share price?
Key factors influencing SAILIFE share price include quarterly earnings growth (Sales Growth: 35.88%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sai Life Sciences Ltd a good stock for long-term investment?
Sai Life Sciences Ltd shows a 5-year Profit Growth of 17.57% and an ROE of 11.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing in SAILIFE shares.
How does Sai Life Sciences Ltd compare with its industry peers?
Sai Life Sciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare SAILIFE share price P/E of 64.17x and ROE of 11.05% against the industry averages to determine competitive standing.
What is the P/E ratio of SAILIFE and what does it mean?
SAILIFE share price has a P/E ratio of 64.17x compared to the industry average of 31.77x. Investors pay ₹64 for every ₹1 of annual earnings.
How is SAILIFE performing according to Bull Run's analysis?
SAILIFE has a Bull Run fundamental score of 48.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SAILIFE belong to?
SAILIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sai Life Sciences Ltd share price.
What is Return on Equity (ROE) and why is it important for SAILIFE?
SAILIFE has an ROE of 11.05%, which shows decent profitability but room for improvement. ROE measures how efficiently Sai Life Sciences Ltd generates profits from shareholders capital.
How is SAILIFE debt-to-equity ratio and what does it indicate?
SAILIFE has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk.
What is SAILIFE dividend yield and is it a good dividend stock?
SAILIFE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sai Life Sciences Ltd shares.
How has SAILIFE share price grown over the past 5 years?
SAILIFE has achieved 5-year growth rates of: Sales Growth 18.49%, Profit Growth 17.57%, and EPS Growth N/A%.
What is the promoter holding in SAILIFE and why does it matter?
Promoters hold 34.93% of SAILIFE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sai Life Sciences Ltd.
What is SAILIFE market capitalisation category?
SAILIFE has a market capitalisation of ₹18379 crores, placing it in the Mid-cap category.
How volatile is SAILIFE stock?
SAILIFE has a beta of N/A. A beta > 1 suggests the Sai Life Sciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SAILIFE operating profit margin trend?
SAILIFE has a 5-year average Operating Profit Margin (OPM) of 19.31%, indicating the company's operational efficiency.
How is SAILIFE quarterly performance?
Recent quarterly performance shows Sai Life Sciences Ltd YoY Sales Growth of 35.88% and YoY Profit Growth of 101.98%.
What is the institutional holding pattern in SAILIFE?
SAILIFE has FII holding of 22.49% and DII holding of 29.95%. Significant institutional holding often suggests professional confidence in the Sai Life Sciences Ltd stock.